DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reminyl (Galantamine Hydrobromide) - Summary

 
 



REMINYL SUMMARY

REMINYL® (galantamine hydrobromide) is a reversible, competitive acetylcholinesterase inhibitor.

REMINYL® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.


See all Reminyl indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Reminyl (Galantamine)

Alzheimer's disease: rAAV/ABAD-DP-6His attenuates oxidative stress induced injury of PC12 cells
Source: Neurology / Neuroscience News From Medical News Today [2014.08.23]
The effects of Amyloid beta (A╬▓)-A╬▓-binding alcohol dehydrogenase (ABAD) may exacerbate Alzheimer's disease pathology.

Alzheimer's disease: are we close to finding a cure?
Source: Clinical Trials / Drug Trials News From Medical News Today [2014.08.20]
There seems to be more focus than ever on Alzheimer's research. But how close are scientists to developing effective prevention and treatment strategies for the disease?

Zebrafish help to unravel Alzheimer's disease
Source: Stem Cell Research News From Medical News Today [2014.08.20]
New fundamental knowledge about the regulation of stem cells in the nerve tissue of zebrafish embryos results in surprising insights into neurodegenerative disease processes in the human brain.

Examining the brain's chromosomal make-up in relation to Alzheimer's disease
Source: Genetics News From Medical News Today [2014.08.19]
A new study led by researchers at Brigham and Women's Hospital (BWH) and Rush University Medical Center, reveals how early changes in brain DNA methylation are involved in Alzheimer's disease.

DNA methylation in brain 'linked to Alzheimer's disease'
Source: Genetics News From Medical News Today [2014.08.18]
Analyzing samples from 708 donated brains, researchers have discovered that changes to the human genome caused by DNA methylation may contribute to onset of Alzheimer's disease.

more news >>

Published Studies Related to Reminyl (Galantamine)

Long-term response to galantamine in relation to short-term efficacy data: pooled analysis in patients with mild to moderate Alzheimer's disease. [2011.03]
BACKGROUND: This analysis aimed to identify an operational, clinically relevant definition of response achieved in short-term clinical trials to support the identification of patients with Alzheimer's disease (AD) who would benefit most from long-term galantamine therapy... CONCLUSIONS: Patients who demonstrate improvement, stability, or limited cognitive decline 2-5 months after reaching maintenance doses of galantamine are more likely to experience continued benefit from long-term galantamine therapy.

Galantamine improves sustained attention in chronic cocaine users. [2011.02]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. [2011.02]
CONCLUSION: Galantamine showed no ameliorative effects on cognitive measures in this 6month, double-blind study of patients with schizophrenia treated with an assured and stable antipsychotic medication delivery system. Galantamine may not be an appropriate augmentation agent for cognitive impairments in patients with schizophrenia at the dose used. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial. [2011]
Galantamine improved symptoms in Alzheimer's disease (AD) patients after 5 to 6 months of treatment... Treatment was generally safe and well tolerated.

Galantamine improves sustained attention in chronic cocaine users. [2011]
Chronic cocaine users are known to have cognitive deficits that are predictive of poor treatment response. Whether these deficits improve with medications targeting specific cognitive functions has not been examined in previous studies.

more studies >>

Clinical Trials Related to Reminyl (Galantamine)

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning [Active, not recruiting]
The purpose of the study is to see if galantamine HBr (Razadyne) is safe and can help treat problems with thinking and memory caused by electroconvulsive therapy (ECT).

A Study of the Safety and Effectiveness of Galantamine Hydrobromide (REMINYL«) in Patients With Alzheimer's Disease [Completed]
The purpose of this study is to evaluate the safety and effectiveness of galantamine hydrobromide (REMINYL«) in patients with Alzheimer's disease who have not received or have not responded to treatment with medication similar to galantamine hydrobromide (REMINYL«).

Effects of Galantamine on Cognition [Recruiting]
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier. Such cognitive impairments and negative symptoms but much milder are also observed in high-risk groups (such as relatives of schizophrenia patients), who may or may not develop the full blown psychotic disorder. Our study plans to recruit such non-ill subjects to test the effects of galantamine on clinical/physiological/cognitive measures. This study serves several goals: If a drug is found effective in treating subtle deficits, then it will provide treatment strategy in individuals with schizophrenia spectrum personality disorders and for early intervention in schizophrenia. In addition, one of the difficulties of testing a drug on schizophrenia is that patients take other medications (i. e., antipsychotic drugs) that can change the effects of the test drug. The proposed study will be in subjects who will not be taking antipsychotic medications. Our study will be carried out in two sessions, at least one month apart. Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing. We will administer a battery of clinical/cognitive/neurophysiological tests after the 8 mg drug dose.

A Single Dose, Cross-Over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy Volunteers [Completed]
The purpose of this open-label, single dose, two-treatment, two-period, cross-over study is to evaluate the pharmacokinetic profile and tolerability of galantamine oral solution and galantamine tablet.

Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl´┐Ż) [Recruiting]
Alzheimer's disease (AD) is characterized by progressive subcortical and cortical neuronal degeneration. AD patients differ in the time course of neuronal degeneration and accompanying cognitive decline.

With recent advances in MR imaging, including optimized data acquisition and processing techniques, tools that are especially well suited for tracking long-term pathological changes as well as drug treatment effects have become available. In addition to structural imaging, new acquisition and analysis techniques have been developed to determine integrity of subcortical fiber tracts in vivo.

In the present project we propose to determine predictors of disease progression and treatment response and investigate potential treatment effects on structural disease progression, covering the continuum from axonal degeneration to cortical neuronal loss taking advantage of recent advances in MRI acquisition and analysis techniques.

more trials >>


Page last updated: 2014-08-23

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014